Abstract:Antimalarial drug resistance has thrown a spanner in the works of malaria elimination. New drugs are required for ancillary support of existing malaria control efforts. Plasmodium falciparum requires host glucose for survival and proliferation. On this basis, P . falciparum hexose transporter 1 ( Pf HT1) protein involved in hexose permeation is considered a potential drug target. In this study, we tested the antimalarial activity of some compounds against Pf HT1 using computational techniques. We performed high throughput virtual screening of 21,352 small-molecule compounds against Pf HT1. The stability of the lead compound complexes was evaluated via molecular dynamics (MD) simulation for 100 nanoseconds. We also investigated the pharmacodynamic, pharmacokinetic and physiological characteristics of the compounds in accordance with Lipinksi rules for drug-likeness to bind and inhibit Pf HT1. Molecular docking and free binding energy analyses were carried out using Molecular Mechanics with Generalized Born and Surface Area (MMGBSA) solvation to determine the selectivity of the hit compounds for Pf HT1 over the human glucose transporter (hGLUT1) orthologue. Five important Pf HT1 inhibitors were identified: Hyperoside (CID5281643); avicularin (CID5490064); sylibin (CID5213); harpagoside (CID5481542) and quercetagetin (CID5281680). The compounds formed intermolecular interaction with the binding pocket of the Pf HT1 target via conserved amino acid residues (Val314, Gly183, Thr49, Asn52, Gly183, Ser315, Ser317, and Asn48). The MMGBSA analysis of the complexes yielded high free binding energies. Four (CID5281643, CID5490064, CID5213, and CID5481542) of the identified compounds were found to be stable within the Pf HT1 binding pocket throughout the 100 nanoseconds simulation run time. The four compounds demonstrated higher affinity for Pf HT1 than the human major glucose transporter (hGLUT1). This investigation demonstrates the inhibition potential of sylibin, hyperoside, harpagoside, and avicularin against Pf HT1 receptor. Robust preclinical investigations are required to validate the chemotherapeutic properties of the identified compounds.

Understanding Interactions between a Potential Antimalarial 'MAL2-11B' and its Targets using In Silico Methods

Structure-Based Virtual Screening, Insilico Docking, ADME Prediction, and Molecular Dynamics Studies for Identification of Potential NMT Inhibitors Against Malaria

Antimalarial drug discovery against malaria parasites through haplopine modification: An advanced computational approach

Iso-mukaadial acetate and ursolic acid acetate bind to Plasmodium Falciparum heat shock protein 70: towards targeting parasite protein folding pathway

An in silico quest for next-generation antimalarial drugs by targeting Plasmodium falciparum hexose transporter protein: a multi-pronged approach

Auto QSAR-based Active learning docking for hit identification of potential inhibitors of Plasmodium falciparum Hsp90 as antimalarial agents

Investigating PI3P Binding with Plasmodium Falciparum HSP70 Proteins

Structural Exploration of the PfBLM Helicase-ATP Binding Domain and Its Implications in the Quest for Antimalarial Therapies

Unveiling Potential Repurposed Drug Candidates for Plasmodium falciparum through In Silico Evaluation: A Synergy of Structure-based Approaches, Structure Prediction, and Molecular Dynamics Simulations

Discovery of dual-target natural antimalarial agents against DHODH and PMT of Plasmodium falciparum: pharmacophore modelling, molecular docking, quantum mechanics, and molecular dynamics simulations

Exploring Harmala Alkaloids as Novel Antimalarial Agents against Plasmodium falciparum through Bioinformatics Approaches

In silico investigation of falcipain-2 inhibition by hybrid benzimidazole-thiosemicarbazone antiplasmodial agents: A molecular docking, molecular dynamics simulation, and kinetics study

Identification of novel Plasmodium falciparum dihydroorotate dehydrogenase inhibitors for malaria using in silico studies

In Silico Screening for Identification of Novel Anti-malarial Inhibitors by Molecular Docking, Pharmacophore Modeling and Virtual Screening.

Molecular docking, simulation and binding free energy analysis of small molecules as PfHT1 inhibitors.

Investigation on Anti‐plasmodial Agents Against wild‐type PfDHFR Through In Silico Computational Tools

Novel Dipeptide Inhibitors of PfPNP: In‐silico Identification of Promising New Antimalarials

Design and Synthesis of Small Molecular Dual Inhibitor of Falcipain-2 and Dihydrofolate Reductase As Antimalarial Agent

In silico Comparison of Novel Proteins from Plasmodium Falciparum as Candidate Drug Targets against Malaria

Plasmodium falciparum heat shock proteins as antimalarial drug targets: An update

In silico prediction and in vitro assessment of novel heterocyclics with antimalarial activity